London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulm ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...

British drug maker GSK plc (GSK, GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data ...

Anti-seizure medications, which are also called anticonvulsants or anti-epileptic drugs (AEDs), are medications used to prevent seizures for people who have epilepsy. All AEDs are available only by ...

Thymic stromal lymphopoietin (TSLP) is an IL-7 cytokine produced by epithelial and stromal cells in the lung and acts as an ...

the inclusion of two new drugs—ensifentrine and dupilumab—into the COPD treatment algorithm, and the management of patients currently treated with long-acting β-agonists (LABA) and inhaled ...

The perspectives and priorities of people living with chronic obstructive pulmonary disease (COPD) should be integrated into ...